2023 World Conference on Lung Cancer (Posters)-P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab

P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab - PDF(Abstract)

Back to course

Pdf Summary

This study examines the prognostic value of changes in platelet volume for patients with metastatic non-small cell lung cancer (NSCLC) treated with pembrolizumab, an immune checkpoint inhibitor. The researchers conducted a retrospective study involving 292 patients who received pembrolizumab monotherapy or combination therapy with chemotherapy. Platelet count and mean platelet volume (MPV) were measured at baseline and at the time of cycle 2. The study found that decreasing MPV during early treatment with pembrolizumab was associated with improved overall survival and increased rate of immune-related adverse events. Patients who received pembrolizumab in combination with chemotherapy had a greater decline in MPV compared to those on pembrolizumab monotherapy. Patients with positive MPV had a higher risk of death. Thrombocytosis at baseline and cycle 2 were also associated with increased risk of death. In multivariate analysis, MPV was found to be associated with overall survival after adjusting for other factors such as ECOG performance status, PD-L1 expression, and baseline platelet count. The study concludes that increasing platelet volume, baseline thrombocytosis, and cycle 2 thrombocytosis are associated with decreased overall survival in patients with metastatic NSCLC receiving pembrolizumab-based treatment. The researchers recommend further translational and basic science research to investigate the underlying mechanisms.

Asset Subtitle

Mingjia Li

Meta Tag

Speaker Mingjia Li

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

platelet volume

metastatic non-small cell lung cancer

NSCLC

pembrolizumab

immune checkpoint inhibitor

retrospective study

chemotherapy

mean platelet volume

overall survival

immune-related adverse events